Thymalfasin pegol

Drug Profile

Thymalfasin pegol

Alternative Names: PEG-TA 1; PEG-Talpha1; PEG-thymalfasin; PEG-thymosin alpha 1; Pegylated thymalfasin - Jiangsu Hansoh Pharmaceutical; Pegylated thymosin alpha 1; Polyethylene glycol thymalfasin; Polyethylene glycol thymosin alpha1; Thymosin alpha pegol

Latest Information Update: 03 Mar 2015

Price : $50

At a glance

  • Originator Jiangsu Hansoh Pharmaceutical
  • Developer Jiangsu Hansoh Pharmaceutical; Nanjing Medical University
  • Class Antineoplastics; Antivirals; Oligopeptides; Polyethylene glycols; Thymus hormones
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatitis B

Most Recent Events

  • 01 Aug 2013 Phase-III clinical trials in Hepatitis B (Combination therapy) in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top